Company Invests $3 million in Equipment and Talent in its Centralized Stability Testing Lab
Patheon , a leading global provider of high-quality drug development and delivery solutions to the pharmaceutical and biopharma sectors, is investing more than $3 million to expand its Greenville, N.C. site's stability testing capabilities. The expansion includes the addition of the most advanced automated systems and the assembly of a highly experienced scientific team to enhance its centralized stability lab offerings.
Since 2011, more than 1,000 stability studies with 110 different products have been initiated at Patheon's stability lab in Greenville. With this expansion, the facility now offers more than 30,000 cubic feet of state-of-the-art stability storage, and the capabilities to support the largest, most complex projects on small molecule APIs, large molecule biologics and drug substances, solid oral dose drugs, sterile liquid or lyophilized drugs, controlled substances and highly potent compounds.
"Our complete suite of advanced analytical tools dedicated to stability testing delivers accelerated results for customers' late-stage development and commercial projects, providing high-quality data in 30 days or less," said Bill Weiser, Ph.D., executive director and global head of analytical sciences. "An additional benefit is that the stability lab's high-tech chromatography system will be fully integrated with the data reporting system which allows customers to access their data anytime, anywhere allowing for quicker access to submission-ready reports."
Patheon is a recognized leader in quality, and the investment in its Greenville facility demonstrates the company's commitment to continued growth and customer needs. Companies facing costly upgrades to their in-house stability capabilities will benefit greatly from the use of Patheon's efficient and cost-effective centralized stability services.
Patheon Media Relations
Tel: +1 (919) 210-0986
Email: [email protected] or [email protected]
About Patheon
Patheon, a business unit of DPx Holdings B.V., delivers a combination of unrivaled quality, reliability and compliance, with a reputation for scientific and technical excellence to customers in the pharmaceutical and biopharma sector. A leading global provider with more than 8,000 employees worldwide, Patheon has a comprehensive set of solutions to help customers of all sizes satisfy complex development and manufacturing needs at any stage of the pharmaceutical development cycle. For more information, visit http://www.patheon.com .